

Grifols appoints Montse Ribas as Chief Communications and Reputation Officer to strengthen the company's global reputation

- *Montse Ribas will oversee the communication and reputation of the company globally, enhancing its leadership in the plasma sector*
- *Previously she managed media relations and institutional affairs for Puig in Spain for 25 years*

Barcelona, Spain, April 3, 2025 - Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), a global healthcare company and leading producer of plasma-derived medicines, today announced it has named Montse Ribas Chief Communications and Reputation Officer. This appointment represents a strategic move for Grifols, which seeks to expand the company's awareness and further enhance its global reputation. As Chief Communications and Reputation Officer, Montse Ribas will prioritize strengthening trust with stakeholders and underscoring the company's excellence and vision. Her responsibilities include global communications and reputation management, as well as the definition and implementation of the strategy for institutional relations.

Montse Ribas has led corporate communications, communications and reputation strategy, and institutional relations for Puig in Spain for the past 25 years. She holds a degree in Business Administration and two master's degrees from ESADE in Business Management and Corporate Communication. Her extensive background covers media relations, crisis communications, corporate transformation and the organization of major institutional events.

"I am delighted to welcome a renowned professional like Montse Ribas, who has had an outstanding and successful career," said **Grifols CEO Nacho Abia**. "Her deep knowledge of reputation management, communications and institutional relations, together with her extensive experience, will be decisive for Grifols. With her excellent experience and strategic mindset, I am convinced that she will do a great job to ensure Grifols' ongoing leadership in plasma medicines and diagnostic solutions."

Montse Ribas is excited for the future with the company. "I am proud to be part of a global standout such as Grifols, with 115 years of commitment to the well-being of people," Ribas said. "Grifols is a pioneering company that has helped create the plasma-derivatives industry, positioning itself as a top-three player. I am committed to promoting Grifols' vision and conveying to all stakeholders the important contributions the company makes to people's health as well as its work to achieve the privileged position it occupies today in the global healthcare industry."

MEDIA CONTACTS:

Grifols Press Office

media@grifols.com

Tel. +34 93 571 00 02

About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. A leader in essential plasma-derived medicines and transfusion medicine, the company develops, produces and provides innovative healthcare services and solutions in more than 110 countries.

Patient needs and Grifols' ever-growing knowledge of many chronic, rare and prevalent conditions, at times life-threatening, drive the company's innovation in both plasma and other biopharmaceuticals to enhance quality of life. Grifols is focused on treating conditions across four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.

A pioneer in the plasma industry, Grifols continues to grow its network of donation centers, the world's largest with close to 400 across North America, Europe, Africa and the Middle East, and China.

As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion, in addition to clinical diagnostic technologies. It provides high-quality biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products. The company also supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 23,800 employees in more than 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

The company's class A shares are listed on the Spanish Stock Exchange, where they are part of the IBEX-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information about Grifols, please visit www.grifols.com

LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are 'projections and future hypotheses'. Words and expressions such as 'believe', 'expect', 'anticipate', 'predict', 'hope', 'intend', 'should', 'will try to achieve', 'is estimated', 'future' and similar expressions, insofar as they refer to the Grifols group, are used to identify future projections and hypotheses. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a series of factors that mean that the real results may be materially different. The future results of the Grifols group could be affected by events related to its own activities, such as shortages of supplies of raw materials for the manufacture of its products, the appearance on the market of competing products, or changes in the regulatory framework of the markets in which it operates, among others. At the date of preparation of this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. assumes no obligation to publicly report, revise or update the projections or future hypotheses to adapt them to facts or circumstances after the date of writing of this report, except when expressly required by applicable legislation. This document does not constitute an offer or invitation to purchase or subscribe shares in accordance with the provisions of Law 6/2023, of 17 March, on the Securities Markets and Investment Services, and any regulations implementing said legislation. Furthermore, this document does not constitute an offer to purchase, sell or exchange, or a solicitation of an offer to purchase, sell or exchange any securities, or a solicitation of any vote or approval in any other jurisdiction. The information contained in this document has not been verified or revised by the external auditors of the Grifols group.